RestorGenex Corporation — Q1 2014 Form 10-Q
Issuer identification: The request metadata names Cervomed Inc., but the supplied filing is for RestorGenex Corporation, formerly Stratus Media Group, Inc. This summary reflects the filing provided. Reporting period: three months ended March 31, 2014; unaudited.
Business context
RestorGenex was repositioning as a specialty biopharmaceutical company focused on dermatology, ophthalmology and women’s health. It acquired Paloma Pharmaceuticals and VasculoMedics on March 28, 2014, following its 2013 acquisition of Canterbury and Hygeia, and discontinued ProElite operations effective March 31, 2014. The company completed a 1-for-100 reverse stock split and changed its name in March. Its development-stage products and research programs had not generated revenue.
Financial performance and position
| Metric | Q1 2014 / March 31, 2014 | Comparable period / prior year-end |
|---|---|---|
| Revenue and gross profit | $0 | $0 in Q1 2013 |
| Operating expenses | $1.372 million | $2.093 million in Q1 2013 |
| Net loss | $1.380 million per financial statements | $2.477 million total net loss in Q1 2013; $2.601 million attributable to common shareholders |
| Loss per share | $0.23 basic and diluted | $2.91 total basic and diluted in Q1 2013 |
| Operating cash flow | $(433,000) | $(306,000) in Q1 2013 |
| Cash and equivalents | $222,000 | $255,000 at December 31, 2013 |
| Total assets | $26.448 million | $18.344 million at December 31, 2013 |
| Current liabilities | $10.695 million | $8.878 million at December 31, 2013 |
| Notes payable | $2.932 million; $717,000 of promissory notes were in default | $1.867 million at December 31, 2013 |
| Accumulated deficit | $62.464 million | — |
There was no gross margin because the company had no revenue. Operating expenses fell by $721,000 year over year, chiefly because prior-year stock and warrant compensation was substantially higher; depreciation and amortization rose, including amortization of acquired intangibles and prepaid advisory fees. Cash used in operations exceeded the prior-year amount, while $400,000 of new notes provided financing. The filing reports negative working capital of $8.017 million and states that cash paid for interest and income taxes was zero.
Reporting inconsistency: The statements report net loss of $1.380 million, while MD&A gives $1.376 million as the period’s loss in several places. The filing does not clearly reconcile this difference.
Material changes, outlook and risks
- Acquisitions and balance sheet: Paloma and VasculoMedics added $2.770 million of intangible assets and goodwill allocations; total goodwill was $13.963 million and intangible assets were $9.725 million. The Paloma intangible valuation was preliminary and subject to third-party valuation. Acquired businesses had no Q1 revenue; Paloma and VasculoMedics closed at quarter-end and contributed no reported-period operating expenses.
- Subsequent financing: On April 29 and May 6, 2014, the company raised $24.779 million gross and $21.528 million net by selling 6,194,625 shares at $4.00, plus warrants for 2,477,851 shares at $4.80. The filing cautions proceeds may not fund growth and acquisitions fully. The pro forma balance sheet shows cash of $21.750 million if net proceeds are added to quarter-end cash; it is not the reported March 31 balance sheet.
- Going concern and obligations: Management disclosed recurring losses, limited liquidity, negative working capital and defaulted notes, raising substantial doubt about the company’s ability to continue as a going concern. Unpaid deferred salary was $838,000. Contractual obligations were reported at $11.112 million. Management said the post-quarter financing might still be insufficient and additional capital could be needed.
- Business outlook: Management expected its CL-214 aging-skin product to be ready for a Ferndale Pharma Group launch in Q2 2015 and planned Phase II studies of P529 for age-related macular degeneration. These are stated plans, not quantified financial guidance; the filing provides no revenue, earnings or cash-flow guidance.
- Impairment and tax: Management concluded no impairment existed on a company-wide basis, but said reporting-unit impairment testing would begin with the quarter ending June 30, 2014. Goodwill and intangible assets totaled $23.688 million and could be subject to substantial impairment. Federal and California net operating loss carryforwards were $48.480 million and $45.235 million, respectively, but a 100% valuation allowance was recorded; ownership changes may limit their use.
- Legal and settlement matters: A creditor-financing arrangement left a $1.582 million liability to be settled through stock issuance; the firm’s share sales could pressure the stock price. The company also accrued $393,592 for a property-damage claim while disputing insurance coverage. Subsequent vendor and former employee/director settlements involved $875,000 of liabilities settled with cash and stock valued at $1.095 million, producing a reported $220,000 loss.
- Controls: Management concluded disclosure controls were ineffective, citing inadequate segregation of duties, a lack of written controls (especially over contracts and commitments), and accounting software controls that allow significant changes without oversight.
Most important facts for investors to verify
- Confirm the intended issuer: the supplied 10-Q is RestorGenex Corporation’s, not Cervomed Inc.’s.
- Reconcile the $1.380 million versus $1.376 million reported Q1 loss figures and confirm the correct comparative EPS basis.
- Review the post-quarter financing’s net proceeds, warrant terms, resulting dilution and subsequent use of funds, including repayment or settlement of obligations.
- Assess near-term liquidity and payment status of defaulted notes, deferred salaries, accrued interest and other contractual obligations.
- Monitor progress and financing needs for the product programs, the CL-214 launch timetable, P529 Phase II plans, and completion of acquisition valuations and reporting-unit impairment tests.
- Track the creditor share-settlement arrangement, property-damage claim and effectiveness of remediation for disclosed control weaknesses.